Recently, FGFR1 amplification was reported to be 9.4% in the cohort with Western Europe.[30] The frequency of high FGFR1 amplification (8.6%), as determined by FISH analysis in our study, was comparable to those reported in previous studies.[13, 29, 30] Given the relatively high frequency of FGFR1 amplification, it may represent an attractive therapeutic target for ESCC. Here, FGFR1 is linked to esophageal squamous cell carcinoma.